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Abstract The nef gene of human and simian immunodeficiency
virus is a key factor in acquired immunodeficiency syndrome
pathogenesis and virus replication. Several Nef-induced phenom-
ena, including the down-regulation of CD4 molecule, have been
previously reported. In this study, we have identified and cloned a
novel cellular protein Naf1 (Nef-associated factor 1), which
associated with Nef in the yeast two-hybrid system and pull-down
assay. The Naf1 gene generates two isoforms (Naf1K and L)
containing four coiled-coil structures. The Naf1 mRNA is
ubiquitously expressed in human tissues with strong expression
in peripheral blood lymphocytes and spleen. Naf1 overexpression
increased cell surface CD4 expression. Nef suppressed this Naf1-
induced augmentation of CD4 expression, providing a novel
mode of Nef action in CD4 down-regulation.
z 1999 Federation of European Biochemical Societies.
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1. Introduction
Progression of acquired immunode¢ciency syndrome
(AIDS) is closely related to human and simian immunode¢-
ciency virus (HIV and SIV) replication [1]. In human, nef-
defective HIV-1 can be isolated from some cases of long-
term non-progressors (reviewed in [2]). In monkey, Nef is
essential for high-titer replication of SIV, and nef-deleted
SIV does not induce AIDS in most cases [2,3]. In humanized
mouse models, nef-defective HIV-1 replicates less e⁄ciently
and shows less profound CD4+ cell depletion than wild-type
HIV-1 [2^4]. Moreover, it has been reported that Nef aug-
ments HIV replication in T cells and macrophages in vitro
[2^4]. Nef associates with several cellular tyrosine kinases
[5^7] and serine/threonine kinases [8,9]. It has been thought
that the interaction between Nef and these kinases may alter
the level of host cellular activation, thus augmenting virion
infectivity [2,3,8,9].
On the other hand, Nef induces down-regulation of cell
surface expression levels of CD4 [2,10] and major histocom-
patibility complex (MHC) class I [11,12] molecules by accel-
erating cellular endocytosis through clathrin-coated pits
(CCPs) [13^15]. This process is dependent on a dileucine motif
within the cytoplasmic tail of CD4 and is thought to be ini-
tiated by the interaction of Nef with CD4 at the plasma mem-
brane [16]. Recently it was found that Nef colocalizes with the
AP-2 complex, which recruits transmembrane proteins to
CCPs, at the plasma membrane and in the region of the Golgi
complex [14]. Furthermore, recent reports have demonstrated
that the Nef-mediated endocytosis occurs through direct in-
teraction between Nef and the W chain of the AP-2 complex
[13,15]. This interaction serves not only to promote formation
of CCPs but also to increase the association of CD4 with the
CCPs [17]. Moreover, Nef also suppressed cell surface CD4
expression levels via additional routes, i.e. inhibition of trans-
port of CD4 from Golgi to plasma membrane and inhibition
of CD4 recycling from endosomes [13,14,18]. Mutational
analysis of Nef showed that augmentation of viral replication
and CD4 down-regulation are separable functions of Nef [19].
The physiological role of CD4 down-regulation remains con-
troversial although possible functional implications in HIV
replication and pathogenesis have been proposed.
As described above, several Nef-mediated phenomena have
been reported. However, there remain many questions about
their molecular mechanisms. Accordingly, we have tried to
identify cellular factors which interact with HIV-1 Nef. Here
we describe a novel Nef binding protein Naf1 (Nef-associated
factor 1) and discuss its modulatory roles in cell surface CD4
expression. Our results might provide a novel mode of Nef
action in CD4 down-regulation.
2. Materials and methods
2.1. Plasmids
To construct pAS2-nefJRÿCSF and pAS2-nefNL4ÿ3, nef ampli¢ed
from infectious HIV-1 clones [20,21] by polymerase chain reaction
(PCR) were inserted in frame into the pAS2 vector (Clontech, Palo
Alto, CA). The nefJRÿCSF was also inserted into pQE32 (Qiagen,
Chatsworth, CA) and pRc/CMV (Invitrogen, Carlsbad, CA) vectors,
resulting in pQE-Nef and pCMV-Nef, respectively. To construct
pCMV-Naf1HA, hemagglutinin (HA) epitope-tagged Naf1L was gen-
erated by PCR and inserted into pRc/CMV. The pCEP/CD4 vector
was donated by Dr. A. Yamashita. The pBCMGS/CD4 and the
pCD19 vectors have been described previously [22,23]. pNL4-3 and
pNL4-3vnef, which encodes nef-minus HIV-1NL4ÿ3, were kindly pro-
vided by Dr. A. Adachi [21].
2.2. Yeast two-hybrid screening
To identify cellular factors that interact with HIV-1 Nef, the
Matchmaker Two-Hybrid System (Clontech) was used. pAS2-
nefJRÿCSF was used as bait in screening of the phytohemagglutinin
(PHA)-stimulated human leukocyte cDNA library (library size
3U106) that was fused to the GAL4 DNA activation domain vector
pGAD10 (Clontech). Positive yeast clones were selected by auxotro-
phy for histidine and expression of L-galactosidase. Plasmids were
harvested from the positive clones and re-examined for their ability
to bind to Nef in the cotransformation assay. cDNA inserts were
characterized by DNA sequencing.
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2.3. cDNA cloning
The 5P- and 3P-rapid ampli¢cation of cDNA ends (RACE) methods
were performed as described [24] using poly(A) RNA extracted from
human skeletal muscle (Clontech). The COILS version 2.0 program
was used to calculate the probability of coiled-coil conformation (28
window width, MTK matrix and weighting of positions a and d) [25].
2.4. Genomic analysis
Cosmids isolated from a chromosome-speci¢c library (Los Alamos
National Laboratory, Los Alamos, NM) were digested with Sau3AI,
AluI, PstI or SstI and shotgun-cloned into M13. Recombinant pla-
ques were screened with restriction fragments of the Naf1 cDNA.
Sequence data generated from the positive clones were compared
with the cDNA sequence and intron-exon boundaries identi¢ed by
comparison with the published consensus sequences [26].
2.5. Northern blot analysis
Northern blot analysis was performed with Multiple Tissue North-
ern (MTN) Blot I and II (Clontech), according to the manufacturer’s
instructions, using a probe corresponding to nucleotides 510^1346 of
the Naf1 cDNA which had been radiolabeled with [32P]K-deoxy-CTP
(NEN Life Science Products, Boston, MA; speci¢c activity of the
probe was 2U108 cpm/Wg). The membranes were analyzed using a
bioimage analyzer BAStation (Fuji¢lm, Tokyo, Japan).
2.6. Cell culture
Human embryonic kidney cell line 293T cells were maintained in
Dulbecco’s modi¢ed Eagle’s medium supplemented with 10% fetal
bovine serum.
2.7. In vitro pull-down assay
The bacteria M15 (pREP4) transformed with pQE-Nef were in-
duced with 1 mM isopropyl thiogalactoside (IPTG) at 30‡C for 2 h.
The lysates were prepared according to the manufacturer’s instruction
(Qiagen). pCMV-Naf1HA was transfected with SuperFect (Qiagen)
into 293T cells, which were plated at a cell density of 2U106 cells
per 10 cm dish 1 day before transfection. Two days later, cell lysates
were extracted with RIPA bu¡er (1% Nonidet P-40, 0.5% sodium
deoxycholate, 0.1% sodium lauryl sulfate (SDS), 1 mM sodium ortho-
vanadate, 2 mM PMSF and 1 Wg/ml aprotinin in phosphate bu¡ered
saline (PBS)) at 4‡C for 30 min, and were cleared by centrifugation.
The bacterial lysates were mixed with the Ni-NTA (nitrilotriacetic
acid) resin (Qiagen) suspended in the binding bu¡er (0.05% Tween
20 and 10% Block Ace (Dai-Nippon Co., Osaka, Japan) in PBS) and
incubated at 4‡C for 1 h with rotation. The Ni-NTA resin was washed
with the washing bu¡er (0.3 M NaCl, 10% glycerol, 10% Block Ace
and 1% Tween 20 in phosphate bu¡er, pH 6.0) and treated with Block
Ace, to reduce the background, at 4‡C for 1 h with rotation. The resin
was then washed with the washing bu¡er, mixed with the 293T cell
lysates and incubated at 4‡C for 1 h with rotation. Following washing,
the complexes were treated with 0.5 M imidazole (Qiagen) for 10 min
at room temperature. The supernatants were subjected to Western
blot analysis, using either an anti-Nef antibody (ABI, Columbia,
MD) or an anti-HA antibody (12CA5; Boehringer Mannheim, Indi-
anapolis, IN).
2.8. Flow cytometry
Cell surface CD4 levels were examined by a modi¢cation of a pre-
viously reported method [16]. In brief, the vectors were cotransfected
with FuGENE (Boehringer Mannheim) into 293T cells, which were
plated at a cell density of 1U105 per six well dish 1 day before trans-
fection. The next day, the cells were harvested and stained with phy-
coerythrin (PE)-conjugated anti-human CD4 antibody (MT310;
Dako, Copenhagen, Denmark) and £uorescein isothiocyanate
(FITC)-conjugated anti-human CD19 antibody (HD37; Dako), and
were subsequently analyzed by FACS Calibur (Becton Dickinson,
Mountain View, CA).
3. Results
3.1. Identi¢cation of a novel Nef-associated factor 1, Naf1
To identify cellular proteins that interact with HIV-1 Nef,
we used the yeast two-hybrid system. The full-length Nef from
HIV-1JRÿCSF, which is a macrophage-tropic strain, was fused
to the GAL4 DNA binding domain. A PHA-stimulated hu-
man leukocyte cDNA library fused to the GAL4 activation
domain was screened. Three His and LacZ transformants
were obtained out of 1.4U107 clones screened and the sequen-
ces of these clones were analyzed using BLAST sequence sim-
ilarity search. Two of the three clones were found to encode a
src-family tyrosine kinase Hck, which has been reported to
associate with Nef through its SH3 (src homology 3) region
[27,28], and an R subunit of chaperonin containing T-complex
protein (CCTR). The third clone contained part of the open
reading frame (ORF) of a novel cellular protein, because it
showed no signi¢cant homologies to sequences in GenBank
except sequences submitted as EST and cDNA fragment with
putative ORF. This clone also associated with Nef from a
di¡erent HIV-1 strain, T cell-tropic HIV-1NL4ÿ3, in the yeast
two-hybrid system (Fig. 1). We termed this novel cellular pro-
tein Naf1 (Nef-associated factor 1) and analyzed it further.
3.2. Cloning of the full-length cDNA and the gene for Naf1
To isolate full-length Naf1 cDNA, the RACE technique
was used. Naf1 cDNA fragments containing 5P and 3P ends
were isolated, resulting in assembly of the entire Naf1 cDNA
(Fig. 2). Analysis of the isolated full-length cDNA clones
revealed that Naf1 has two isoforms (Naf1K and L) with dif-
ferent C-termini (Fig. 2). The molecular weight calculated
from the deduced amino acid sequences of Naf1K/L is approx-
imately 72 kDa. Both isoforms contain a proline-rich region
within the C-terminal 100 amino acids, in which 24% of ami-
no acids are prolines. A data base search revealed that the
full-length Naf1 cDNA had weak homology with some pro-
teins containing coiled-coil structures. Using the COILS algo-
rithm [25], Naf1K/L were predicted to contain four coiled-coil
structures (Fig. 2). The region through which Naf1 binds to
Nef is located within amino acids 94^412 (Fig. 2). We also
elucidated the genomic structure of the gene encoding Naf1.
This gene consists of 18 exons; the ¢rst exon is untranslated
and exons 2^18 contain the coding sequence (Fig. 2). The
genomic structure indicated that Naf1K/L are produced by
alternative splicing; Naf1L mRNA is synthesized when a splic-
ing acceptor site within exon 18 is utilized (Fig. 2). The Naf1
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Fig. 1. Association of Naf1 with Nef from HIV-1JRÿCSF and HIV-
1NL4ÿ3 in the yeast two-hybrid system. Histidine auxotrophy of the
yeast transformants was analyzed. The CG1945 yeast strain was co-
transformed with GAL4 DNA binding domain vectors (pAS2,
pAS2-nefJRÿCSF and pAS2-nefNL4ÿ3) and GAL4 activation domain
vectors (pGAD424 and Naf1). The transformants were seeded on
control medium lacking Leu and Trp (left panel) and medium lack-
ing Leu, Trp and His (right panel). The only transformants in
which Nef interacted with Naf1 could form colonies in the medium
lacking Leu, Trp and His, and had increased L-galactosidase activity
(data not shown).
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gene is located on human chromosome 5q32^33.1 (data not
shown).
3.3. Naf1 expression in human tissues
The expression of Naf1 mRNA in human tissues was exam-
ined by Northern blot analysis. This revealed that the 2.8 kb
Naf1 mRNA is ubiquitously expressed with strong expression
in peripheral blood lymphocytes, spleen and skeletal muscle
and weak expression in brain (Fig. 3). The mRNA was also
detected in various human hematopoietic cell lines, for exam-
ple, MOLT-4, Jurkat and HL60 (data not shown).
3.4. Association of full-length Naf1 and Nef
The yeast two-hybrid study demonstrated that a part of
Naf1 associated with Nef from two di¡erent HIV-1 strains.
Next, we examined whether the full-length Naf1 associates
with Nef by pull-down assay. Initially, we produced Nef fu-
sion protein (Nef-6UHis) containing six consecutive histidine
residues in its N-terminus in bacteria (Fig. 4, left panel). Be-
cause Ni-NTA resin binds to hexahistidine, the bacterial ex-
tract containing the Nef-6UHis and the control extract were
mixed with the Ni-NTA resin. On the other hand, HA-tagged
Naf1L (Naf1-HA) was produced in human 293T cells (Fig. 4,
middle panel). Then, the cell extracts were incubated with Ni-
NTA resin that had been pretreated with bacterial extracts.
Proteins bound to the resins were eluted using imidazole, and
Western blot analysis was performed using anti-HA antibody.
As shown in the right panel of Fig. 4, Naf1-HA was pulled
down together with Nef-6UHis-bound resin but only back-
ground level was associated with unbound resin, indicating
that the full-length Naf1 speci¢cally associates with Nef in
the presence of human cellular extracts.
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Fig. 2. The nucleotide and amino acid sequences of full-length Naf1K/L. Full-length Naf1K/L was characterized by cDNAs obtained by yeast
two-hybrid screening and the 5P- and 3P-RACE methods. Probability of coiled-coil conformation was calculated as described in Section 2. The
four underlines show putative coiled-coil structures. Alternative splicing produced Naf1K/L. The arrowheads show alternative splicing sites at
1987 nt (Naf1K, open arrowhead) and 2061 nt (Naf1L, solid arrowhead). The Nef interacting region is enclosed. The bars indicate borders of
exons.
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3.5. Augmentation of cell surface CD4 expression by Naf1
We studied whether Naf1 a¡ects cell surface CD4 expres-
sion. For this purpose, we chose a well-established model,
often used to examine the turnover of CD4 molecule such
as Nef-mediated CD4 down-regulation [28]. The CD4 expres-
sion vector pBCMGS/CD4 was cotransfected into 293T cells
with increasing amounts of Naf1-HA expression vector, and
cell surface CD4 expression was examined by £ow cytometric
analysis. To evaluate the transfection e⁄ciency, the CD19
expression plasmid was also cotransfected. The cell surface
CD19 expression level was not a¡ected by Naf1 overexpres-
sion (data not shown). As shown in Fig. 5A, the cell surface
CD4 expression level was increased by Naf1-HA expression to
a maximum of 2.5-fold in a dose-dependent manner. We con-
¢rmed that the Naf1 protein level was linearly increased when
the amounts of transfected plasmids increased (data not
shown). We next transfected pBCMGS/CD4 at various doses.
The cell surface CD4 level linearly increased with the amounts
of transfected plasmids (Fig. 5B). The Naf1-induced enhance-
ment of CD4 expression occurred within a broad range of
CD4 expression levels (Fig. 5B). Similar results were obtained
when another CD4 expression vector, pCEP/CD4, was trans-
fected (data not shown). Thus, Naf1-HA expression could
increase cell surface CD4 expression.
Next, we examined whether Nef alters Naf1-induced aug-
mentation of CD4 expression. When Nef expression plasmid
was transfected, CD4 levels were reduced by 60% (Fig. 5C),
which is consistent with the level of down-regulation described
in previous reports using the same system [16]. In the presence
of Naf1, Nef still decreased CD4 expression levels by 40%,
although the absolute CD4 levels were higher compared to
those in the absence of Naf1 (Fig. 5C). In addition, the vec-
tors of HIV-1 infectious clones, pNL4-3 and pNL4-3vnef,
were transfected instead of Nef expression vector. As shown
in Fig. 5D, when Nef was co-expressed with Naf1 in the
context of full-length HIV-1, Naf1-induced CD4 augmenta-
tion was again inhibited but absolute CD4 levels were higher
than those of Naf1-untransfected cells. These results indicated
that the ratio of Nef and Naf1 could a¡ect the cell surface
CD4 expression levels. In addition, HIV-1 production was
analyzed by an HIV-1 p24gag enzyme-linked immunosorbent
assay (ELISA) (Lumipulse f, Fujirebio, Tokyo). Virus produc-
tion was similar despite di¡erent levels of cell surface CD4
expression (data not shown).
4. Discussion
In this study, we identi¢ed and cloned the novel cellular
protein Naf1. This Naf1 protein associated with HIV-1 Nef
in a yeast two-hybrid system and in a pull-down assay using
transfected human cell lysates. Moreover, we showed that
Naf1 overexpression increased cell surface CD4 levels and
that Nef overexpression inhibited this Naf1-induced CD4 aug-
mentation. Similar results in cell surface CD4 levels were ob-
served when Nef was expressed in the context of an infectious
HIV-1 clone.
Nef promotes CD4 down-regulation via multiple pathways,
i.e. enhancement of CD4 endocytosis [3], inhibition of its
transport from Golgi to plasma membrane [18] and inhibition
of its recycling [13]. Recently, it was proposed that Nef-in-
duced CD4 endocytosis is mediated by the complex formation
containing Nef, CD4, AP-2 and V-ATPase [13,29]. It still
remains unclear which CD4 turnover process step is a¡ected
by Naf1. Considering that Naf1 has four extended coiled-coil
structures, it is supposed that Naf1 interacts with cellular and/
or viral proteins to regulate the turnover of the CD4 molecule.
From this viewpoint, it is noteworthy that many coiled-coil
proteins such as SNAREs [30,31] bind each other between
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Fig. 3. Naf1 mRNA expression in human tissues. Northern blot
analysis was performed with using Multiple Tissue Northern (MTN)
Blot I and II (Clontech) containing 2 Wg of human poly(A) RNA
in each lane, according to the manufacturer’s instructions. The used
probe was Nef interacting region of the Naf1 cDNA that had been
radiolabeled. Names of the tissues are shown at the top of the pan-
el.
Fig. 4. In vitro pull-down assay of Nef and Naf1. Left panel: Nef-
6UHis fusion protein. Bacterial lysates were collected from IPTG-
induced (lane 1) and uninduced (lane 2) bacteria. The proteins puri-
¢ed by Ni-NTA resin were resolved by 15% SDS-PAGE. The gel
was stained with Coomassie brilliant blue (CBB) (lanes 1 and 2).
The Nef-6UHis was also con¢rmed by Western blot analysis with
anti-Nef antibody (data not shown). The sizes of a prestained
marker (Bio-Rad, Hercules, CA) are shown. Middle panel: Naf1-
HA protein. The human embryonic kidney cell line 293T cells were
transfected with pCMV-Naf1HA (lane 3) and pRc/CMV (lane 4).
The lysates were resolved by 8% SDS-PAGE and subjected to West-
ern blot analysis with an anti-HA antibody. The sizes of kaleido-
scope marker (Bio-Rad) are shown. Right panel: Ni-NTA resin
pull-down assay. The 293T cell lysate containing Naf1-HA was div-
ided and mixed with Ni-NTA resin pretreated with the lysates from
IPTG-induced (lane 5) and uninduced (lane 6) bacteria. The pro-
teins bound to the resin were washed three times with washing buf-
fer, pulled down and analyzed by Western blot analysis with anti-
HA antibody. As shown in lane 5, Naf1-HA was pulled down with
Nef speci¢cally. The sizes of kaleidoscope marker are shown. These
experiments were repeated three times with similar results.
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vesicular and plasma membranes, thereby regulating vesicle
tra⁄cking, sorting and fusion events. When overexpressed,
these coiled-coil-containing proteins often accumulate in spe-
ci¢c membrane compartments, change the morphology of
these compartments and a¡ect the rate of vesicle tra⁄cking,
sorting and fusion. Similar to these proteins, immunostaining
of Naf1-HA-transfected cells showed punctate staining within
cytoplasm which appeared to be the enlarged membrane com-
partments (M. Fukushi, unpublished data), implicating its
possible involvement in membrane tra⁄cking and sorting
events.
Naf1 binds to Nef in the yeast two-hybrid system and in the
in vitro pull-down assay using mammalian cell lysates. Be-
cause of a lack of anti-Naf1 antibodies against endogenous
Naf1, we performed immuno-pull-down assays with Naf1-HA
and Nef-cotransfected cell lysates. However, detection of in-
teraction in mammalian cells was unsuccessful. One of the
reasons for the inability to detect their interaction in vivo is
Naf1 accumulation in restricted cellular compartments as de-
scribed above. Generation of antibodies to detect endogenous
Naf1 is necessary for further clari¢cation of this point.
Given Naf1’s coiled-coil structure, cellular localization and
ability to augment the CD4 molecule, we envisage that Naf1
may positively modulate cell surface CD4 expression presum-
ably during the tra⁄cking and sorting processes, and Nef may
inhibit Naf1 function through a physical association. From
this point of view, Nef may down-regulate cell surface CD4
levels by two distinct molecular mechanisms: (i) activation of
cellular pathways which down-regulate CD4 such as activa-
tion of CCP-mediated endocytosis, and (ii) inhibition of cel-
lular pathways which up-regulate CD4 such as inhibition of
Naf1 action. Further studies are required to determine how
and at which step Naf1 could a¡ect cell surface CD4 expres-
sion. When these aspects of Naf1 action are made clear, we
may obtain a new twist in the mechanism of Nef-induced CD4
down-regulation.
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